Columbus Circle Investors’s Esperion Therapeutics ESPR Stock Holding History

Columbus Circle Investors’s Portfolio ESPR Stock Details ESPR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-254,704	Closed	-$18.4M	–	198
2018 Q1	$18.4M	Buy	254,704 +167,675	+193%	+$12.3M	0.37%	98
2017 Q4	$5.73M	Buy	87,029 +35,032	+67%	+$1.89M	0.11%	147
2017 Q3	$2.61M	Buy	+51,997	New	+$2.51M	0.04%	212
2016 Q2	–	Sell	-1,115,467	Closed	-$18.9M	–	266
2016 Q1	$18.9M	Buy	1,115,467 +61,015	+6%	+$981K	0.17%	126
2015 Q4	$23.5M	Buy	1,054,452 +315,541	+43%	+$7.96M	0.19%	120
2015 Q3	$17.4M	Buy	738,911 +197,797	+37%	+$12.4M	0.14%	141
2015 Q2	$44.2M	Buy	541,114 +293,919	+119%	+$28.8M	0.31%	80
2015 Q1	$22.9M	Buy	247,195 +241,062	+3,931%	+$15.6M	0.16%	140
2014 Q4	$248K	Buy	+6,133	New	+$188K	﹤0.01%	286

Other funds holding ESPR

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Aviva Holdings New Providence, Bahamas $20.5M AUM 117.01% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Columbus Circle Investors's ESPR Position: Q2 2018 in Review

Columbus Circle Investors sold out of Esperion Therapeutics (ESPR) in Q2 2018, closing a stake of 254,704 shares — an estimated $18.4M sold.

Columbus Circle Investors first reported a position in ESPR in Q4 2014 and held it in 9 quarters. The position peaked at $44.2M in Q2 2015. 156 funds tracked by Wall St. Rank hold ESPR as of Q2 2018.

Columbus Circle Investors reported no remaining Esperion Therapeutics position as of Q2 2018 after selling out during the quarter.
Columbus Circle Investors sold 254,704 Esperion Therapeutics shares in Q2 2018, an estimated $18.4M.
Columbus Circle Investors first reported a position in Esperion Therapeutics in Q4 2014 and held it in 9 quarters.
Columbus Circle Investors's Esperion Therapeutics position peaked at $44.2M in Q2 2015.
156 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q2 2018.

Based on Columbus Circle Investors's 13F filing for Q2 2018, filed 24 Jul 2018.